COMPANY

Amydis Diagnostics

HQ: Los Angeles, CA source · amydis.com ↗ · West Coast

Keywords: ophthalmology digital health neurology Cerebral Amyloid Angiopathy multiple system atrophy Alzheimer Disease Parkinson Disease Amyotrophic Lateral Sclerosis Primary Open Angle Glaucoma alzheimer's disease prion disease AMDX-2011P AMDX2011P

Location: Los Angeles, CA · source · Oct 13, 2026

Profile checked Oct 10, 2026

4Trials (company is sponsor)15NIH grants

Funding and NIH signals

NIH award NIH awarded $1.11M (SBIR Phase II 5R44AG078075-03, continuation, notice Jul 10, 2026). NIH RePORTER 5R44AG078075-03 (Jul 10, 2026)
Evidence (1 event)
- Jul 10, 2026 · NIH RePORTER 5R44AG078075-03
  Organization: AMYDIS DIAGNOSTICS, INC.; City/State: La Jolla, CA; Project number: 5R44AG078075-03; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-07-10; FY total cost (award amount): 1107817; Administering IC: National Institute on Aging; Project title: Development of a topical tracer to detect TDP43 in ALS, LATE and FTD retinas for AI-powered disease insights; Organization type: Domestic For-Profits

Job counts as of Oct 18, 2026. All funding and NIH signals

Timeline

Jul 10, 2026 Grant Government grant — SBIR: $1.11M (annual award, as published), announced Jul 10, 2026. Agency: NIH/NIA. Source: government award database. source ↗
Sep 9, 2025 Grant Government grant — SBIR: $1.39M (annual award, as published), announced Sep 9, 2025. Agency: NIH/NIA. Source: government award database. source ↗
Mar 7, 2025 Trial start Phase 2: A Study of AMDX-2011P in Participants With Alzheimer's Disease source ↗
Jul 9, 2024 Trial start Phase 2: A Study of AMDX-2011P in Participants With CAA source ↗
Dec 7, 2023 Trial start Phase 2: A Study of AMDX-2011P in Participants With Primary Open Angle Glaucoma source ↗
Aug 24, 2022 Trial start Phase 1/Phase 2: Study of AMDX-2011P as a Retinal Tracer in Subjects With Neurodegenerative Diseases Associated With Amyloidogenic Proteinopathy source ↗

Upcoming milestones

2026-12 (ESTIMATED) · Phase 2 · A Study of AMDX-2011P in Participants With CAA · NCT05709314
2027-07 (ESTIMATED) · Phase 2 · A Study of AMDX-2011P in Participants With Alzheimer's Disease · NCT06514001

Estimated primary completion per ClinicalTrials.gov. Dates move.

Funding

Last 2 years.

Jul 10, 2026 Government grant — SBIR: $1.11M (annual award, as published), announced Jul 10, 2026. Agency: NIH/NIA. Source: government award database. source ↗
Sep 9, 2025 Government grant — SBIR: $1.39M (annual award, as published), announced Sep 9, 2025. Agency: NIH/NIA. Source: government award database. source ↗

Clinical trials (lead sponsor) 4

Record	Title	Phase	Status	Start	Primary completion
NCT06514001	A Study of AMDX-2011P in Participants With Alzheimer's Disease	Phase 2	Recruiting	Mar 7, 2025	2027-07 (estimated)
NCT05709314	A Study of AMDX-2011P in Participants With CAA	Phase 2	Recruiting	Jul 9, 2024	2026-12 (estimated)
NCT05542576	Study of AMDX-2011P as a Retinal Tracer in Subjects With Neurodegenerative Diseases Associated With Amyloidogenic Proteinopathy	Phase 1/Phase 2	Completed	Aug 24, 2022	Mar 15, 2023 (actual)
NCT06223048	A Study of AMDX-2011P in Participants With Primary Open Angle Glaucoma	Phase 2	Unknown status (ClinicalTrials.gov)	Dec 7, 2023	2024-11 (estimated)

NIH awards 15

Annual award amounts. Total $15.1M.

Sep 3, 2024 NIH award 5SB1AG050454-05 FY2024: $1,715,680 awarded for that fiscal year; activity SB1 (SBIR); PI SARRAF, STELLA; recipient as written: AMYDIS DIAGNOSTICS, INC., La Jolla, CA. Use of novel fluorescent tracers to dev source ↗
Sep 20, 2023 NIH award 2SB1AG050454-04A1 FY2023: $1,704,372 awarded for that fiscal year; activity SB1 (SBIR); PI SARRAF, STELLA; recipient as written: AMYDIS DIAGNOSTICS, INC., La Jolla, CA. Use of novel fluorescent tracers to d source ↗
Aug 20, 2022 NIH award 5R44NS124473-02 FY2022: $900,109 awarded for that fiscal year; activity R44 (SBIR); PI SARRAF, STELLA; recipient as written: AMYDIS DIAGNOSTICS, INC., La Jolla, CA. Differential diagnosis of Parkinson's and source ↗
Aug 12, 2022 NIH award 1R43AG078075-01 FY2022: $458,527 awarded for that fiscal year; activity R43 (SBIR); PI SARRAF, STELLA; recipient as written: AMYDIS DIAGNOSTICS, INC., La Jolla, CA. Development of a novel fluorescent tracer source ↗
Jul 22, 2022 NIH award 5SB1AG073029-02 FY2022: $1,442,787 awarded for that fiscal year; activity SB1 (SBIR); PI SARRAF, STELLA; recipient as written: AMYDIS DIAGNOSTICS, INC., La Jolla, CA. Development of an ophthalmic diagnostic source ↗
Sep 22, 2021 NIH award 1R44NS124473-01 FY2021: $2,077,573 awarded for that fiscal year; activity R44 (SBIR); PI SARRAF, STELLA; recipient as written: AMYDIS DIAGNOSTICS, INC., La Jolla, CA. Differential diagnosis of Parkinson's a source ↗
Aug 26, 2021 NIH award 1R43AG071089-01A1 FY2021: $492,212 awarded for that fiscal year; activity R43 (SBIR); PI SARRAF, STELLA; recipient as written: AMYDIS DIAGNOSTICS, INC., La Jolla, CA. Development of Novel Tau Retinal Tracer source ↗
May 28, 2021 NIH award 1SB1AG073029-01A1 FY2021: $1,590,883 awarded for that fiscal year; activity SB1 (SBIR); PI SARRAF, STELLA; recipient as written: AMYDIS DIAGNOSTICS, INC., La Jolla, CA. Development of an ophthalmic diagnost source ↗
Jun 5, 2020 NIH award 5R44AG058350-03 FY2020: $1,049,456 awarded for that fiscal year; activity R44 (SBIR); PI SARRAF, STELLA; recipient as written: AMYDIS DIAGNOSTICS, INC., La Jolla, CA. Development of a novel ophthalmic probe source ↗
Sep 19, 2019 NIH award 2R44AG058350-02 FY2019: $490,250 awarded for that fiscal year; activity R44 (SBIR); PI SARRAF, STELLA; recipient as written: AMYDIS DIAGNOSTICS, INC., La Jolla, CA. Development of a novel ophthalmic probe f source ↗
Sep 17, 2018 NIH award 1R43AG057421-01A1 FY2018: $408,225 awarded for that fiscal year; activity R43 (SBIR); PI SARRAF, STELLA; recipient as written: AMYDIS DIAGNOSTICS, INC., La Jolla, CA. Development of Novel Prion Disease Diag source ↗
Sep 10, 2017 NIH award 1R43AG058350-01 FY2017: $534,525 awarded for that fiscal year; activity R43 (SBIR); PI SARRAF, STELLA; recipient as written: AMYDIS DIAGNOSTICS, INC., La Jolla, CA. Development of a Novel Diagnostic Probe f source ↗
Jul 10, 2017 NIH award 5R44AG050454-03 FY2017: $211,174 awarded for that fiscal year; activity R44 (SBIR); PI SARRAF, STELLA; recipient as written: AMYDIS DIAGNOSTICS, INC., La Jolla, CA. Development of an ophthalmic diagnostic p source ↗
Sep 23, 2016 NIH award 2R44AG050454-02 FY2016: $1,647,908 awarded for that fiscal year; activity R44 (SBIR); PI SARRAF, STELLA; recipient as written: AMYDIS DIAGNOSTICS, INC., La Jolla, CA. Development of an ophthalmic diagnostic source ↗
Sep 18, 2015 NIH award 1R43AG050454-01A1 FY2015: $383,810 awarded for that fiscal year; activity R43 (SBIR); PI SARRAF, STELLA; recipient as written: AMYDIS DIAGNOSTICS, INC., La Jolla, CA. Development of an ophthalmic diagnostic source ↗